23:29 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

DISEASE CATEGORY: Endocrine/metabolic; transplant INDICATION: Diabetes; islet cell transplant Inhibition of PTP-1B in pancreatic islet cell grafts could help improve outcomes in Type I diabetes. In a mouse model of Type I diabetes, knockout of...
01:25 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Cell culture and worm studies suggest the PTP-1B inhibitor trodusquemine could help treat AD. In human cells cultured with β amyloid 42 (Aβ 42 ), trodusquemine decreased the formation of Aβ...
18:55 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a...
22:16 , Nov 16, 2017 |  BC Extra  |  Preclinical News

Disease targets also act as tumor suppressors

Two studies published in the last week suggest that strategies to treat disease, including inhibiting targeting PD-1 or protein tyrosine phosphatase 1B (PTP-1B; PTPN1), can also lead to cancer. PD-1 inhibitors like Keytruda pembrolizumab from...
07:00 , Aug 11, 2016 |  BC Innovations  |  Product R&D

SHP-2 sets sail

Novartis AG researchers have revived a once-promising cancer target - a protein tyrosine phosphatase - by departing from the rote strategy of blocking its active site, and arresting the molecule in its inactive form instead....
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Warp's independence day

Stephen Hansen, Associate Editor   New revelations about the breadth of Warp Drive Bio LLC's platform, coupled with the lengthy biotech boom, led the company and partner Sanofi to toss out their 2012 build-to-buy deal...
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein tyrosine phosphatase 1B (PTP-1B; PTPN1); methyl CpG binding protein 2 (MECP2; RTT)

Neurology INDICATION: Rett syndrome Mouse and patient sample studies suggest inhibiting PTP-1B could help treat Rett syndrome. PTP-1B levels were higher in fibroblasts from Rett syndrome patients than in cells from healthy subjects, and forebrain...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

Cold Spring Harbor Laboratory, GlaxoSmithKline deal

The partners are discovering and developing small molecules to regulate the activity of protein tyrosine phosphatase 1B ( PTP-1B ; PTPN1 ) to treat obesity and Type II diabetes. GSK and Cold Spring will both...
01:21 , Apr 3, 2015 |  BC Extra  |  Company News

Cold Spring Harbor, North Shore-LIJ form cancer partnership

Cold Spring Harbor Laboratory (CSHL) and New York City-area hospital network North Shore-LIJ Health System will jointly invest $120 million in a new oncology research collaboration that will include clinical trials of therapeutic candidates. CSHL...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

ISIS-PTP1BRx: Phase II data

Top-line data from a double-blind, international Phase II trial in 92 obese patients with uncontrolled Type II diabetes showed that once-weekly 200 mg ISIS-PTP1BRx plus metformin and/or a sulfonyurea for 26 weeks led to a...